Imexon

Imexon

Clinical data
ATC code	none
Identifiers
IUPAC name 4-imino-1,3-diazabicyclo[3.1.0]hexan-2-one
CAS Number	59643-91-3 Y
PubChem CID	68791
ChemSpider	62031 N
UNII	8F63U28T2V
KEGG	D08932 Y
CompTox Dashboard (EPA)	DTXSID1046895
ECHA InfoCard	100.056.199
Chemical and physical data
Formula	C4H5N3O
Molar mass	111.104 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C1/N=C(/N)C2N1C2
InChI InChI=1S/C4H5N3O/c5-3-2-1-7(2)4(8)6-3/h2H,1H2,(H2,5,6,8) N Key:BIXBBIPTYBJTRY-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Imexon (INN, trade name Amplimexon) is a substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It is a cyanoaziridine derivative.

• Amplimexon entry in the public domain NCI Dictionary of Cancer Terms

 This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

• v
• t
• e